Tiziana Life Sciences Announces Positive Topline Data from Phase 2a INFORM-MS Trial

Nov 3, 2026, 4:07 AM ETTrialRead the original at globenewswire.com

Good for TLSA

Tiziana reported a drop in a brain-inflammation scan measure at 50 μg, and both doses were well tolerated. The 100 μg dose did not show a significant drop, but the lower-dose result supports the treatment's promise.

TLSA · Tiziana Life Sciences

AI read · Good for TLSA

The AI's read

The results give Tiziana evidence that its nasal treatment may help reduce brain inflammation. Both dose levels were well tolerated, but only the lower dose showed a scan improvement, so the findings are encouraging without showing that more medicine worked better.

Get alerts for TLSA

Follow Tiziana Life Sciences (TLSA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TLSA

Free on the App Store and Google Play, or on the web.